补充短双歧杆菌M-16V对生长受限的极早产儿粪便双歧杆菌的影响——一项随机试验的分析

Effect of Bifidobacterium breve M-16V supplementation on faecal bifidobacteria in growth restricted very preterm infants - analysis from a randomised trial.

作者信息

Patole Sanjay K, Keil Anthony D, Nathan Elizabeth, Doherty Dorota, Esvaran Meera, Simmer Karen N, Conway Patricia

机构信息

a Department of Neonatal Paediatrics , King Edward Memorial Hospital for Women , Perth , Australia .

b Centre for Neonatal Research and Education, University of Western Australia , Perth , Australia .

出版信息

J Matern Fetal Neonatal Med. 2016 Dec;29(23):3751-5. doi: 10.3109/14767058.2016.1147554. Epub 2016 Feb 26.

DOI:10.3109/14767058.2016.1147554

PMID:26821074

Abstract

BACKGROUND

Gut development, function and colonisation are impaired in animal models of prematurity with intrauterine growth restriction (IUGR). The effect of Bifidobacterium breve (B. breve) supplementation on faecal bifidobacteria in small for gestational age (SGA: birth weight <10th centile due to IUGR) preterm infants is not known.

OBJECTIVE

We compared B. breve M-16V supplementation effect on faecal bifidobacteria in preterm (<33 weeks) SGA versus non-SGA infants in the two arms of our randomised controlled trial.

RESULTS

There were no baseline differences in the proportion of detectable B. breve counts between SGA versus non-SGA infants [probiotic: 7 (33%) versus 22 (42%), p = 0.603; placebo: 1 (6%) versus 1 (2%), p = 0.429]. B. breve counts did not differ between SGA and non-SGA infants in response to treatment (p = 0.589), after adjusting for baseline count (p < 0.001) and treatment allocation (p < 0.001). An interaction term between growth status and treatment showed negligible change (p = 0.938). Probiotic treated SGA infants reached full feeds earlier than SGA controls (HR 2.00, 95% CI 1.05-3.82, p = 0.035): Median (IQR): 16 (12-26) versus 19 (11-25) days, after adjustment for age at starting feeds and gestation <28 weeks.

CONCLUSION

Response to B. breve M-16V supplementation was not significantly different in preterm (<33 weeks) SGA versus non-SGA infants.

摘要

背景

在患有宫内生长受限（IUGR）的早产动物模型中，肠道发育、功能及定植均受损。对于小于胎龄儿（SGA：因IUGR导致出生体重低于第10百分位数）早产婴儿，补充短双歧杆菌（B. breve）对粪便双歧杆菌的影响尚不清楚。

目的

在我们的随机对照试验的两个组中，比较补充B. breve M-16V对早产（<33周）SGA婴儿与非SGA婴儿粪便双歧杆菌的影响。

结果

SGA婴儿与非SGA婴儿之间，可检测到的B. breve计数比例在基线时无差异[益生菌组：7例（33%）对22例（42%），p = 0.603；安慰剂组：1例（6%）对1例（2%），p = 0.429]。在调整基线计数（p < 0.001）和治疗分配（p < 0.001）后，SGA婴儿与非SGA婴儿对治疗的B. breve计数无差异（p = 0.589）。生长状态与治疗之间的交互项显示变化可忽略不计（p = 0.938）。经益生菌治疗的SGA婴儿比SGA对照组更早达到全量喂养（风险比2.00，95%置信区间1.05 - 3.82，p = 0.035）：在调整开始喂养时的年龄和孕周<28周后，中位数（四分位间距）分别为16（12 - 26）天和19（11 - 25）天。